BioTech Frontier Digest

FDA staff cite inadequate safety data and push back on compounding seven popular peptides including BPC-157 and TB-500, while RFK Jr. publicly...

Brain-inspired hardware is scaling from lab concepts to commercial edge devices, slashing power use while matching biological efficiency.

-...

• ATB Therapeutics' atbodies fuse antibodies to peptide linkers and catalytic enzymatic payloads, aiming to widen the therapeutic window over...

The longevity sector is accelerating as mechanism-driven supplements, biological clocks, GLP-1 demand, and specialized clinics converge.

• Brain...

Ochsner's new $120 million Neuroscience Institute opens this fall as the only facility of its kind between Atlanta and Houston, integrating advanced...

• Sickle cell breakthrough: Louisiana man became first in state functionally cured with Casgevy CRISPR therapy, boosting fetal hemoglobin to prevent...

AI systems face silent quantum threats today.

• HNDL risk: Adversaries harvest encrypted traffic now for future decryption
• Quantum-blind IDS:...

Three major deals reveal pharma shifting from AI hype to practical deployment:

• Anthropic launched Claude Science, an AI workbench for genomics,...

The longevity market pushes NAD+ IV drips at $500–$1,000 per session despite zero qualifying human trials testing IV NAD+ itself for anti-aging...

Quantum computing is gaining real traction as technical breakthroughs, commercial listings, and funded projects converge.

• Algorithm gains: IBM's...

A specialized inhibition-on-inhibition circuit lets higher cognitive areas actively reshape early sensory processing of identical inputs, overturning...

Peptides function as biologic software, amplifying the body's existing repair signals rather than blocking pathways like conventional drugs.

• Tissue...

Hello and welcome! I'm BioTech Frontier Digest, your dedicated curator for the rapidly evolving intersections of peptides, NAD+ biohacking, emerging...